0.0467479674796749 0.0467479674796749 0.0467479674796749 0.0467479674796749 0.0495528455284553 0.0507520325203253 0.0467479674796749 0.00203252032520339
Sign Up Today X
Thanks for submitting the form.
Stockreport

Moleculin begins NIH-funded Phase II glioblastoma treatment trial [Yahoo! Finance]

Moleculin Biotech, Inc. (MBRX)  More Company Research Source: Yahoo! Finance
Last moleculin biotech, inc. earnings: 8/16 05:35 pm Check Earnings Report
US:NASDAQ Investor Relations: moleculin.com/investors
The trial is being conducted under Northwestern University's Investigative New Drug application, which references Moleculin's own US Food and Drug Administration (FDA)-cleared IND in April 2022. Apart from NIH, BrainUp, a non-profit organisation focusing on creating awareness on brain cancer, is providing additional funding. The open-label, multi-arm study is focusing on newly diagnosed patients with isocitrate dehydrogenase (IDH) wild-type, O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma. The primary goal of the study is to measure progression-free survival, while secondary outcomes include the analysis of the tumour microenvironment. WP1066, an immune/transcription modulator, is designed to enhance the immune response to tumours by hindering regulatory T cells' errant activity and oncogenic transcription factors. The asset obtained orphan drug designation for the treatment of brain tumours and rare pediatric disease designation for three other paed [Read more]
IMPACT SNAPSHOT EVENT TIME: MBRX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
MBRX alerts
from News Quantified
MBRX
NEWS
MBRX
Earnings
MBRX
Analyst Actions
MBRX
SEC Filings
Stockreport

Moleculin begins NIH-funded Phase II glioblastoma treatment trial [Yahoo! Finance]

Moleculin Biotech, Inc.  (MBRX) 
More Company Research Source: Yahoo! Finance
Last moleculin biotech, inc. earnings: 8/16 05:35 pm Check Earnings Report
US:NASDAQ Investor Relations: moleculin.com/investors
The trial is being conducted under Northwestern University's Investigative New Drug application, which references Moleculin's own US Food and Drug Administration (FDA)-cleared IND in April 2022. Apart from NIH, BrainUp, a non-profit organisation focusing on creating awareness on brain cancer, is providing additional funding. The open-label, multi-arm study is focusing on newly diagnosed patients with isocitrate dehydrogenase (IDH) wild-type, O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma. The primary goal of the study is to measure progression-free survival, while secondary outcomes include the analysis of the tumour microenvironment. WP1066, an immune/transcription modulator, is designed to enhance the immune response to tumours by hindering regulatory T cells' errant activity and oncogenic transcription factors. The asset obtained orphan drug designation for the treatment of brain tumours and rare pediatric disease designation for three other paed [Read more]
IMPACT SNAPSHOT
EVENT TIME:
MBRX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS